Anavex Life Sciences is dedicated to advancing brain health by developing innovative oral medicines designed to improve patients lives.
The Journal of Prevention of Alzheimer’s Disease (JPAD) has published peer-reviewed detailed results from the Phase IIb/III study evaluating oral Blarcamesine (ANAVEX®2-73) for the treatment of early Alzheimer’s Disease (AD).